Analysis of FLT3 internal tandem duplication and D835 mutations in Chinese acute leukemia patients

被引:32
作者
Wang, LH
Lin, D
Zhang, XW
Chen, S
Wang, M
Wang, JX
机构
[1] Chinese Acad Med Sci, Inst Hematol, State Key Lab Expt Hematol, Tianjin 300020, Peoples R China
[2] Chinese Acad Med Sci, Blood Dis Hosp, Tianjin 300020, Peoples R China
[3] Peking Union Med Coll, Tianjin 300020, Peoples R China
[4] Chinese Acad Med Sci, Inst Hematol, Dept Clin Hematol, Tianjin 300020, Peoples R China
基金
中国国家自然科学基金;
关键词
acute leukemia; FLT3; mutation;
D O I
10.1016/j.leukres.2005.05.013
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Genomic aberrations of Fins-like tyrosine kinase 3 (FLT3). including internal tandem duplication (ITD) and point mutations. have been demonstrated in 25-30% of adults acute Myeloid leukemia (AML) and are markers of poor prognosis. FLT3/ITD and D835 mutations were analyzed in 194 Chinese patients with acute leukemia and myelodysplastic syndromes (MDS) by polymerase chain reaction (PCR). FLT3/ITDs and D835 Mutations were found in 25.9 and 6.3% of 143 AML patients. respectively. Two patients showed both ITD and point Mutations. Among the FAB subtypes of AML, therateof FLT3 aberration was significantly higher M3 and M5. However, neither aberrations was found in 25 patients with acute lyinphoblastic leukemia (ALL), 2 acute hybrid leukemia, 17 MDS and 7 chronic myeloid leukeinia in blast crisis (CML-BC). FLT3/ITD was associated to leukocytosis and lower complete remission (CR) rate, and was more prevalent in patients with normal karyotype. In contrast. D835 mutation was not associated with leukocytosis or low CR rate. Our results confirm that FLT3 activating Mutations also Occur in a significant percentage in Chinese AML patients. FLT3/ITD+ patients treated with standard induction regimen could achieve lower complete remission rates compared with patients not harboring this defect. Early detection of FLT3 mutations and an intensification of induction therapy might thus be useful for this group of patients to overcome the poor prognosis. (C) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1393 / 1398
页数:6
相关论文
共 19 条
[1]   Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia [J].
Abu-Duhier, FM ;
Goodeve, AC ;
Wilson, GA ;
Care, RS ;
Peake, IR ;
Reilly, JT .
BRITISH JOURNAL OF HAEMATOLOGY, 2001, 113 (04) :983-988
[2]   Genomic structure of human FLT3:: Implications for mutational analysis [J].
Abu-Duhier, FM ;
Goodeve, AC ;
Wilson, GA ;
Care, RS ;
Peake, IR ;
Reilly, JT .
BRITISH JOURNAL OF HAEMATOLOGY, 2001, 113 (04) :1076-1077
[3]   Prognostic significance of FLT3 internal tandem repeat in patients with de novo acute myeloid leukemia treated with reinforced courses of chemotherapy [J].
Boissel, N ;
Cayuela, JM ;
Preudhomme, C ;
Thomas, X ;
Grardel, N ;
Fund, X ;
Tigaud, I ;
Raffoux, E ;
Rousselot, P ;
Sigaux, F ;
Degos, L ;
Castaigne, S ;
Fenaux, P ;
Dombret, H .
LEUKEMIA, 2002, 16 (09) :1699-1704
[4]   Distinct genetic patterns can be identified in acute monoblastic and acute monocytic leukaemia (FAB AML M5a and M5b):: a study of 124 patients [J].
Haferlach, T ;
Schoch, C ;
Schnittger, S ;
Kern, W ;
Löffler, H ;
Hiddemann, W .
BRITISH JOURNAL OF HAEMATOLOGY, 2002, 118 (02) :426-431
[5]   Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia [J].
Kiyoi, H ;
Naoe, T ;
Yokota, S ;
Nakao, M ;
Minami, S ;
Kuriyama, K ;
Takeshita, A ;
Saito, K ;
Hasegawa, S ;
Shimodaira, S ;
Tamura, J ;
Shimazaki, C ;
Matsue, K ;
Kobayashi, H ;
Arima, N ;
Suzuki, R ;
Morishita, H ;
Saito, H ;
Ueda, R ;
Ohno, R .
LEUKEMIA, 1997, 11 (09) :1447-1452
[6]  
Kiyoi H, 1999, BLOOD, V93, P3074
[7]   Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product [J].
Kiyoi, H ;
Towatari, M ;
Yokota, S ;
Hamaguchi, M ;
Ohno, R ;
Saito, H ;
Naoe, T .
LEUKEMIA, 1998, 12 (09) :1333-1337
[8]   The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials [J].
Kottaridis, PD ;
Gale, RE ;
Frew, ME ;
Harrison, G ;
Langabeer, SE ;
Belton, AA ;
Walker, H ;
Wheatley, K ;
Bowen, DT ;
Burnett, AK ;
Goldstone, AH ;
Linch, DC .
BLOOD, 2001, 98 (06) :1752-1759
[9]   FLT3: ITDoes matter in leukemia [J].
Levis, M ;
Small, D .
LEUKEMIA, 2003, 17 (09) :1738-1752
[10]  
Moreno I, 2003, HAEMATOLOGICA, V88, P19